drugset / Trial / NCT03416517
Anlotinib and Irinotecan for Ewing Sarcoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma.
Timeline
- Start
- 2018-01-22
- Primary completion
- 2020-02
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Irinotecan | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 20 mg/m2 | Intravenous |